Rossari Biotech reported record Q4 FY26 revenue of ₹684.9 crore, up 18.2% YoY, with PAT growing 33.7% to ₹46.0 crore.
The company commissioned 15,000 MTPA ethoxylation capacity at Dahej, taking total installed capacity to 66,000 MTPA.
Board recommended a dividend of ₹0.50 per share for FY26 and appointed Udeypaul Singh Gill as Independent Director.
Core B2B segments (HPPC 77%, TSC 17%, AHN 6%) delivered strong growth while Institutional and B2C segments remained subdued.